Chinese Medicine in Treating Insomnia

NCT ID: NCT06511011

Last Updated: 2024-07-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-30

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blinded, placebo-controlled clinical trial. Eligible participants will randomized into either treatment group (CM granules) or placebo group (placebo granules) for 6 weeks, followed by a post-treatment visit at week 9. The primary outcome is the change in Pittsburgh Sleep Quality Index (PSQI) at week 6.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Insomnia is one of the most general health concerns in the society. It is generally defined as a self-reported sleep disorder problem of the patient, characterized by difficulty in falling asleep, or difficulty maintaining sleep. According to American Insomnia Survey, 42.6% of the respondents reported of having at least one of the insomnia symptoms.

Chinese medicine can be an alternative to the treatment of insomnia. Suan Zao Ren Tang and Tian Wang Bu Xin Dan are two of the most common Chinese herbal formulae to treat insomnia, for which Suan Zao Ren Tang has the functions to nourish blood and calm the mind, clear heat and alleviate vexation, and Tian Wang Bu Xin Dan has the function to nourish the heart and calm the mind, and nourish Yin and clear heat. In this study, we will modify the formula of Suan ZaoRen Tang with TianWang BuXin Dan, and observe the effectiveness and safety of the study drug.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insomnia Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mSZT-TBD granules

Modified Suan ZaoRen Tang-TianWang BuXin Dan granules

Group Type EXPERIMENTAL

Modified Suan ZaoRen Tang-TianWang BuXin Dan

Intervention Type DRUG

Chinese medicine granules for 6 weeks

Placebo granules

Placebo granules

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo granules for 6 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Modified Suan ZaoRen Tang-TianWang BuXin Dan

Chinese medicine granules for 6 weeks

Intervention Type DRUG

Placebo

Placebo granules for 6 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

mSZT-TBD Placebo granules

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18 to 65 years;
* Eligible for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria for insomnia disorder. The criteria include having difficulties in falling asleep, difficulties in staying asleep, or early morning awakening with clinically significant consequences for daily life for at least 3 nights per week for at least 6 months;
* Insomnia Severity Index (ISI) total score of at least 8 indicating insomnia at the clinical level;
* Diagnosed to be Yin deficiency-induced internal heat pattern according to traditional Chinese Medicine (TCM) theory;
* Able to complete questionnaires and take medications as scheduled; and
* Voluntary written consent.

Exclusion Criteria

* Known nervous system disease (eg, stroke, Parkinson's Disease);
* Known mental disorders (eg, depression or anxiety) or HADS score 11 or above in any either item;
* Known sleeping related diseases (eg. sleep apnea, nocturnal myoclonus, restless legs, severe nocturnal enuresis or narcolepsy) that may affect the sleeping quality;
* Known pharmacologically induced insomnia;
* With symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturition, and cough;
* Know treatment to comorbid sleep disorders, such as sleep apnea or narcolepsy;
* Work on shift or on night shift;
* Concomitant pharmacological treatment or herbal medicines for insomnia within the past month;
* Known severe medical conditions, such as cardiovascular, liver, kidney or hematopoietic system disease, diabetes mellitus, cancers, cerebrovascular diseases;
* Impaired hematological profile and liver / renal function exceeds the upper limit of the reference value by 2 times;
* Known alcohol and / or drug abuse;
* Known allergic history to any Chinese herbal medicines;
* Diagnosed to be deficiency of spleen according to TCM theory;
* Any contraindications for taking Chinese medicines in the opinion of the investigators;
* Know pregnant or lactating; and
* Involved in other interventional clinical studies at the same time.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Lin Zhixiu

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhixiu Lin

Role: PRINCIPAL_INVESTIGATOR

Chinese University of Hong Kong

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhixiu Lin

Role: CONTACT

Cho Wing Lo

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Insomnia study

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Compound Ciwujia Granules in the Treatment of Insomnia
NCT07306494 NOT_YET_RECRUITING PHASE4
FMT for Insomnia Disorder (FMT-SLEEP)
NCT06606938 NOT_YET_RECRUITING NA
PK/PD Study of YZJ-1139
NCT06685341 COMPLETED PHASE1